{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T13:24:33Z","timestamp":1794835473063,"version":"4.9.1"},"reference-count":27,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T00:00:00Z","timestamp":1652572800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017723","name":"Innovent Biologics (Suzhou) Co., Ltd., Suzhou","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2022,12,31]]},"DOI":"10.1080\/13696998.2022.2071066","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T10:50:57Z","timestamp":1651056657000},"page":"618-629","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":44,"title":["Cost-effectiveness analysis of sintilimab\u2009+\u2009chemotherapy versus camrelizumab\u2009+\u2009chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China"],"prefix":"10.1080","volume":"25","author":[{"given":"Mingjun","family":"Rui","sequence":"first","affiliation":[{"name":"School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, People\u2019s Republic of China"},{"name":"Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, Jiangsu, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyang","family":"Fei","sequence":"additional","affiliation":[{"name":"School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, People\u2019s Republic of China"},{"name":"Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, Jiangsu, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingcheng","family":"Wang","sequence":"additional","affiliation":[{"name":"School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, People\u2019s Republic of China"},{"name":"Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, Jiangsu, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueke","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, People\u2019s Republic of China"},{"name":"Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, Jiangsu, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aixia","family":"Ma","sequence":"additional","affiliation":[{"name":"School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, People\u2019s Republic of China"},{"name":"Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, Jiangsu, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haikui","family":"Sun","sequence":"additional","affiliation":[{"name":"Innovent Biologics (Suzhou) Co., Ltd, Suzhou, Jiangsu, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongchao","family":"Li","sequence":"additional","affiliation":[{"name":"School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, People\u2019s Republic of China"},{"name":"Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, Jiangsu, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,5,15]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_5_3_1","unstructured":"Organization WH. The Global Cancer Observatory. 2021. Accessed 29\/9 2021."},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32130-X"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-021-01022-9"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.11.008"},{"key":"e_1_3_5_7_1","volume-title":"Guidelines of chinese society of clinical oncology (csco) for immune checkpoint inhibitor clinical practice 2021","author":"ONCOLOGY CSOC","year":"2021","unstructured":"ONCOLOGY CSOC. Guidelines of chinese society of clinical oncology (csco) for immune checkpoint inhibitor clinical practice 2021. People 's medical Publishing House; 2021."},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.07.014"},{"key":"e_1_3_5_9_1","unstructured":"Innovent Biologics I. U.S. FDA Accepts Regulatory Submission for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer. 2021. Accessed 10\/27 2021."},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.07.015"},{"key":"e_1_3_5_11_1","volume-title":"China guidelines for pharmacoeconomic evaluations 2020","author":"Liu G","year":"2020","unstructured":"Liu G, Wu J, Wu J, et\u00a0al. China guidelines for pharmacoeconomic evaluations 2020. Beijing: China Market Press; 2020."},{"key":"e_1_3_5_12_1","unstructured":"Woods B Sideris E Palmer S et\u00a0al. NICE DSU technical support document 19: partitioned survival analysis for decision modelling in health care: a critical review. 2017. Available from: http:\/\/www.nicedsu.org.uk"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2021.1893167"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30365-9"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9"},{"key":"e_1_3_5_16_1","unstructured":"Longworth L Rowen D. NICE DSU technical support document 10: the use of mapping methods to estimate health state utility values. 2011. Available from: http:\/\/www.nicedsu.org.uk"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-016-0455-1"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2020.08.018"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12477"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-012-0419-2"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32368"},{"issue":"6","key":"e_1_3_5_22_1","first-page":"567","article-title":"A health state utility model estimating the impact of ivosidenib on quality of life in patients with relapsed\/refractory acute myeloid leukemia","volume":"22","author":"Wehler M-S-S-ke.","year":"2018","unstructured":"Wehler M-S-S-ke. A health state utility model estimating the impact of ivosidenib on quality of life in patients with relapsed\/refractory acute myeloid leukemia. EHA Library. 2018;22(6):567\u2013576.","journal-title":"EHA Library"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780198526629.001.0001"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-019-00812-6"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S178934"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00886-2"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/0962280214557578"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-019-0709-9"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2022.2071066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T11:21:45Z","timestamp":1729164105000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2022.2071066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,15]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12,31]]}},"alternative-id":["10.1080\/13696998.2022.2071066"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2022.2071066","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,15]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-12-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}